To evaluate the correlation between tumor mutational load and objective response rate, Yarchoan et al. plotted the objective response rate for PD-1 or anti-PD-L1 (PD ligand 1) therapy against median tumor mutational load across 27 tumor types/subtypes. Here, CD274 is linked to neoplasm.